-
APASL 2025 | Dr. Yinying Lu’s Team Unlocks New Multidimensional Strategies in Liver Cancer Treatment
Among the notable contributions, the research team led by Dr. Yinying Lu from the Fifth Medical Center of the PLA General Hospital presented several significant findings on liver cancer treatment.…
-
Allogeneic Transplant Outcomes in Severe Aplastic Anemia: What Role Does Donor Type Play?
At the EBMT 2025 Annual Meeting, Dr. Juan Montoro Gómez (La Fe University and Polytechnic Hospital, Valencia) presented key findings from a comparative study led by the SAAWP of the…
-
Relapsed B-ALL Post CAR-T Therapy: Addressing a Growing Clinical Challenge | EBMT 2025
In his EBMT 2025 presentation, Prof. Alessandro Rambaldi (University of Milan / ASST Papa Giovanni XXIII, Bergamo) offered valuable insight into one of the most pressing issues in hematologic oncology:…
-
Late Effects After Auto-HSCT in Autoimmune Diseases: A Call for Long-Term Monitoring
At the EBMT 2025 annual meeting, Dr. Kirill Kirgizov presented findings from a comprehensive retrospective survey (GS2-10) on late complications following autologous hematopoietic stem cell transplantation (HSCT) for autoimmune diseases…
-
Clonal Hematopoiesis in Pediatric HCT Survivors: New Insights from Dr. Konradin Müskens at EBMT 2025
At the 51st EBMT Annual Meeting, Dr.Konradin Müskens (Prinses Máxima Centrum voor kinderoncologie, Netherlands) presented findings from the GS2-4 session on “Prevalence and Origin of Clonal Hematopoiesis in Long-Term Survivors…
-
Understanding Relapse After Allo-HCT: Dr. Luca Vago Sheds Light on Biological Complexity and Future Solutions
At EBMT 2025, Dr. Luca Vago delivered a compelling presentation titled “Mechanisms of Leukemia Relapse after Allogeneic Transplantation: From Biology to Treatment (and Back).” His talk focused on the intricate…
-
Predicting Graft Failure in Pediatric HCT: Key Insights from EBMT 2025
At the 51st Annual Meeting of EBMT, Dr. Rawad Rihani from the King Hussein Cancer Center (Jordan) delivered an important presentation on the determinants and outcomes of graft failure (GF)…
-
CD123 CAR T & Engineered NK Cells: Emerging Hope in R/R AML
At EBMT 2025, Dr. Rémy Duléry (Dana-Farber Cancer Institute) presented highly promising data on novel immunotherapeutic strategies for relapsed/refractory AML. While CD123-targeted CAR T-cell therapy has shown limited long-term survival…
Connecting Medical Expertise through Media